Tuesday, March 8, 2016

FDA Concedes Defeat on Off-Label Drug Marketing

(MedPage Today) -- Amarin can market its fish-oil product (Vascepa) for unapproved indications
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)